Erickson AW, Habbous S, Wright F, et al. - Patients with intracranial metastatic disease (IMD) and ERBB2-positive breast cancer, EGFR-positive lung and bronchus cancer, or BRAF-positive melanoma appeared to exhibit improved survival in correlation with receiving targeted therapies.

• This cohort study was performed including 26,676 patients with IMD.

• Patients with IMD and ERBB2 (formerly HER2)–positive breast cancer, EGFR-positive lung and bronchus cancer, or BRAF-positive melanoma who received targeted therapy showed prolonged survival when compared with those who did not.

• Patients with IMD, vs those without, reported shorter survival among patients with metastatic ERBB2-positive breast cancer or EGFR-positive lung and bronchus cancer, but not among BRAF-positive melanoma.